Drilldown: Medicines

Solifenacin (1)

Vesicare (1)

[[:Category:Antimuscarinics|Antimuscarinic (M3-selective)]] (1) · [[:Category:Overactive_bladder_medications|Overactive bladder medication]] (1)

'"`UNIQ--vote-00000DFA-QINU`"' CYP3A4 substrate; QT-interval prolongation has been reported at higher doses. Like other antimuscarinics, contributes to cumulative anticholinergic burden in older adults'"`UNIQ--ref-00000DFB-QINU`"'. (1)

'"`UNIQ--vote-00000DFC-QINU`"', '"`UNIQ--vote-00000DFD-QINU`"' (1)

5 mg PO once daily; titrate to 10 mg after 2 weeks if needed (1)

5, 10 mg tablets (1)

10 mg/d (5 mg if severe renal or moderate hepatic impairment, or strong CYP3A4 inhibitors) (1)

Oral (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

None · 24 hours · 4-6 hours · 12 hours · 6-8 hours · Daily dosing · 8-12 hours · 12-24 hours · Hours · Hours per application · 24 hours (HS dosing) · 24 hours (once-daily dosing) · 24 h · N/A · N/A (replacement) · Variable · ~7-8 hours · 3-5 hours · 4-6 hours (IR); 24 hours (ER) · 6-12 hours

Other values:

Search

~45-68 hours'"`UNIQ--ref-00000DFE-QINU`"' (1)

~90% (oral)'"`UNIQ--ref-00000DFF-QINU`"' (1)

Limited data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

[[USLegal:Prescription only|Rx-only]] in US (1)